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Monetary valuations of the economic cost of health care–associated infections (HAIs) are important for decision making and
should be estimated accurately. Erroneously high estimates of costs, designed to jolt decision makers into action, may do
more harm than good in the struggle to attract funding for infection control. Expectations among policy makers might be
raised, and then they are disappointed when the reduction in the number of HAIs does not yield the anticipated cost saving.
For this article, we critically review the field and discuss 3 questions. Why measure the cost of an HAI? What outcome should
be used to measure the cost of an HAI? What is the best method for making this measurement? The aim is to encourage
researchers to collect and then disseminate information that accurately guides decisions about the economic value of expanding
or changing current infection control activities.
Because health care resources are scarce, they should be allo-
cated to programs that deliver quantifiable health benefits. A
rule of thumb for decision making is that the more benefit
gained per dollar spent, the better [1]. This applies to those
working to reduce the number of health care–associated in-
fections (HAIs). They should aim to allocate their budget across
infection prevention strategies that deliver the largest possible
health benefit [2–5]. To demonstrate the “biggest bang for your
buck” argument, estimates of how health benefits (the bang)
and costs (the buck) change with the adoption of novel infec-
tion control interventions are required [3, 6]. That increasing
investment for infection control is economically justified is not
questioned. HAI is a major problem that prolongs hospital
stays, prevention is relatively cheap, and many prevention strat-
egies are effective [7]. Whether the economic argument has
always been made in the best way and whether optimal analyt-
ic methods have been used to estimate the primary economic
parameters are worth discussion.
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Many decisions about expanding infection control have been
based on partial economic studies that show only the gross cost
of an HAI [8, 9]. Costing studies may influence decision makers
because the estimated gross cost per HAI has been found to be
very high, and the conclusion that the cost saved from expanding
infection control will exceed the cost incurred is assumed to be
true without rigorous analysis. To evaluate completely a new
infection control strategy requires accurate estimates of the extra
cost of implementing the strategy, the cost savings from the
predicted number of prevented cases of HAI, and the clinical
effectiveness and health benefits. Simple costing studies that show
the gross costs of an HAI are partial evaluations and provide
none of this information [10]. Good decision making about
infection control should emerge from cost-effectiveness research
[11, 12]. Those working for infection control are publishing
complete economic appraisals at a rate faster than before [13–
16], and this is positive. This research often makes use of mod-
eling studies with various pieces of information harvested from
the literature. A key piece of information is the cost per case of
HAI, which informs, albeit indirectly, the expected cost saving
from extra infection control [17].
Data are now emerging that seriously question the validity
of previously applied methods used to determine the cost of
an HAI [18–25]. The main cost of an HAI is the extra stay in
the hospital. Estimates of extra length of stay based on sounder
statistical methods tend to show a shorter estimated extra stay,
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which means that the cost of an HAI may have previously been
overestimated [18]. Also problematic is the method used to
attach monetary value to lost bed-days, which is often based
on cost accounting practices and not economic principles—yet
these 2 disciplines have quite different objectives. There may
be serious problems with how the economic costs of an HAI
have been estimated. Given the importance of estimates of the
cost of an HAI for decision making, we are motivated to discuss
the approaches used. Three important questions are considered;
our aim is to stimulate research that accurately guides decision
making about the economics of changing current infection con-
trol activities.
WHY MEASURE THE COST OF AN HAI?
The primary reason to understand the cost of an HAI is to
inform decisions about how to reduce the problem [2–5]. Be-
cause health care resources are scarce, HAIs should be reduced
by allocating resources only to efficient infection control pro-
grams. One approach is to maximize the amount of health
gained from a defined pot of resources. This is called an ex-
trawelfarist view of economics [26] and is used widely in health
services decision making [27]. Other approaches to solving
resource allocation problems are available [28], and their merits
have been debated elsewhere [26, 29–31].
The extrawelfarist approach uses a conceptually simple rule
to guide decision making. The change to cost from a decision
to adopt a new health intervention (such as a novel infection
control intervention) should be adequately compensated by the
change to health benefit. Changes to cost are summarized in
monetary terms, and changes to health benefit are normally de-
scribed by means of quality-adjusted life-years (QALYs), which
combine information on the quantity and quality of years of life
gained [28, 32]. The number of QALYs gained from infection
control demonstrate improved quality of care, because lives are
saved and events that reduce the quality of life for hospital pa-
tients are avoided.
The extrawelfarist decision rule can be written as
DC/DE ! l ,
where DC is the total dollar costs under a new intervention
less the total dollar costs under an appropriate comparator
(usually the existing practice), DE is the change in health out-
comes that arises from a decision to invest in a new health
intervention (the total number of QALYs under a new inter-
vention less the total number of QALYs under an appropriate
comparator), and l is the decision maker’s maximum willing-
ness to pay for each QALY. Challenges exist for the analyst who
quantifies the change to QALYs (health benefits) from infection
control, and a critique of these is beyond the scope of this article.
When the decision rule is met, those working under an extrawel-
farist economics framework might adopt the new intervention
on the grounds that it promotes efficiency. If ,DCp 100
, and , the rule is met and the intervention shouldDEp 5 lp 30
be adopted. Finding an appropriate value for l is not straight-
forward [33]. The value varies in practice, often to accommodate
other important objectives, such as equity and fairness [28]. The
use of the extrawelfarist decision rule for infection control has
been discussed in detail elsewhere [3].
For infection control decisions, the change in cost statistic
(DC) arises from 2 opposing forces. The first is that costs always
increase with a decision to implement extra infection control
strategies. The second is that cost savings arise from avoided
cases of HAI. Because the cost of a case of HAI affects the value
of DC, it is important to estimate costs with accuracy. Oth-
erwise, the DC statistic will be incorrect, and bad decisions may
result.
WHAT OUTCOME SHOULD BE USED
TO MEASURE THE COST OF AN HAI?
The number of bed-days lost to a case of HAI is an appropriate
outcome to describe a large proportion of the cost, and this
number can be represented by the letter q. The marginal number
of bed-days released by reducing the rate of HAIs may well have
a positive economic value or price, which can be elicited from
the appropriate source and represented by the letter p. A large
part of the cost of an HAI is, therefore, the quantity of bed-days
saved (q) multiplied by their economic value or price (p)—or
pq. The remainder of the costs of an HAI arise from consumable
items used to treat the infection and from physician fees that are
billed separately. The consumables saved can result in substantial
cost savings, such as when a bloodstream infection leads to septic
shock. Very expensive drugs might be required and a high volume
of other consumable items used. More modestly, a treatment
protocol for respiratory infection due to methicillin-resistant
Staphylococcus aureus may account for less costly consumables.
It will be hard to identify exactly the extra physician fees that
arise from treating an HAI, but concurrent attribution methods
may be useful for this task [34].
We propose that counting the number of bed-days saved first
(q) and valuing them in dollar terms second (p) is a powerful
method for describing much of the economic cost of an HAI.
Our reasons emerge from considering the different objectives of
the hospital-based cost accountant and the public policy econ-
omist. The rest of this section is about finding a value for p, and
the next section is about the methods used for estimating q.
A public policy economist would take a different approach
than a cost accountant to valuing p. The economist would
investigate the value of the bed-days in the next best alternative
use and so seek the economic opportunity cost incurred from
using it to treat an HAI. The accountant would estimate the
cash expenditures made to supply the average bed-day. These
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2 values for p are likely to be different, because health care is
an unusual commodity in economic terms [35]. Yet the value
for p is critical for decision making about investments for in-
fection control. Those who make the argument for extra in-
vestment in infection control are making an economic argu-
ment. They wish to reallocate scarce resources toward infection
control and thus away from the supply of some other health-
producing activity. They must therefore consider the oppor-
tunity cost of the marginal bed-day. Using data collected by
hospital accountants to find p may lead to erroneous decisions
about new infection control strategies. We explain the reasons
for the divergent valuations of p by considering the objectives
of the hospital accountant and then the economist.
The hospital accountant strives to keep the organization fi-
nancially viable for current and future annual budgeting cycles;
the objective is to maintain a going concern [36]. In this task,
hospital accountants face a high proportion of fixed costs, up to
85% [37, 38]. Examples of fixed costs are power, information
and finance systems, and the salaries of many staff. They must
recover all the fixed and variable costs of supplying hospital care.
Variable costs are those not fixed and can be assigned to indi-
vidual patients on the basis of use. For example, the number of
antibiotics or bags of saline used can be counted and the cash
expenditures added to a patient’s bill. Fixed costs are likely to
be used jointly by many patients over an annual budgeting cycle.
Hospital accountants will allocate fixed costs by surrogate mea-
sures of activity—such as bed-days, tests ordered, or units of
staff time—and then count the units of each measure assigned
to patients. The majority of hospital costs are allocated by length
of stay [39–41]. If rates of HAIs fall, fewer bed-days, tests, or
units of staff time are used, but the cash expended on fixed costs
will not change. The result is spare capacity in the hospital, and,
unless it is redeployed for new patients, the average fixed cost
recovered for every unit of activity (eg, a bed-day) will rise. Cost
estimates that emerge from accounting departments are mana-
gerial costs designed to recover total expenditures for an annual
budgeting cycle. They are a convenient way to keep the hospital
financially viable and arise from measures of patient throughput.
Accounting costs are not designed to represent the economic
value of the marginal health care resources released from a re-
duction in the number of HAIs [42].
The economist will focus on the marginal number of bed-
days and other resources released and on the cash from saved
variable costs. Economists will ignore the expenditures made
for fixed costs that correctly occupy accountants. These are
irrelevant to any decision about allocating scarce resources for
new infection control strategies, because they will not change
with lower rates of HAIs. The marginal number of bed-days
released by infection control may, however, take a positive eco-
nomic value in some other use. They can be used to increase
productivity and treat more patients. Their opportunity cost is
the value that someone is willing to pay to access the marginal
bed-day. As long as the effective demand exceeds the supply
for hospital-based services, then marginal bed-days will be val-
uable items in economic terms.
In a decentralized system (such as in the United States), the
next patient or his or her insurance company may be willing
to pay a certain price (p) to access the bed-days released by
the positive effect of extra infection control. In a centrally man-
aged health care system (such as the UK National Health Ser-
vice) that is owned by the public sector, politicians and bu-
reaucrats can be asked their willingness to pay for hospital
bed-days given other demands on public sector spending. One
scenario is that there is zero demand for newly released bed-
days, so their opportunity cost is zero (ie, ). This is un-pp 0
likely when we consider the long waiting lists and large pool
of unmet health needs in almost every jurisdiction. If oppor-
tunity costs are positive, then the value is likely to vary. Local
demand conditions may play a role. If patients face long wait-
ing lists for elective admission, there are demands for higher
throughput by hospitals, and no new building programs are
planned to increase supply, then marginal bed-days may be
valued higher than in a jurisdiction with less severe constraints.
The perspective of the person making the valuation may also
play a role. If an election is looming and a politician has prom-
ised to improve health care services by treating more patients
in hospitals and reducing waiting lists, he or she will put a high
value on extra bed-days. If, however, the chief executive of the
hospital believes that adequate compensation for any extra pa-
tients admitted will not be provided, he or she may see only
an increased workload and level of stress for the hospital’s staff
and so attach a lower economic value to bed-days released. This
view will, of course, be tempered by a desire to provide high-
quality services, and this improvement in quality is described
by the gain in health benefits (QALYs) used in cost-effectiveness
research.
WHAT IS THE BEST METHOD
FOR MAKING THIS MEASUREMENT?
Because costs are strongly dependent on length of stay, we need
to accurately measure the extra length of stay caused by a case
of HAI (q). Any method used should account for the fact that
HAIs arise at different times during a hospital stay in different
patients and that other factors influence length of stay, such as
primary diagnosis and comorbidity. A seminal article on meth-
odology [34] compared physician assessment with matched co-
hort studies, where infected patients are matched with uninfected
control subjects on variables thought likely to cause an excess
stay. Physician assessments provide the ideal measure but are
time-consuming; matched cohort studies are easier to conduct
but suffer from 2 sources of bias. The first bias arises because
some patients are predisposed to a long hospital stay regardless
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of HAI status, and matching on confounding variables is not
able to control all the bias. The second bias arises from increasing
the number of matching variables in an attempt to control the
first bias, as this often causes infected individuals to be selected
out of the study because the pool of uninfected control subjects
is exhausted. In matched cohort studies, one can only find the
best tradeoff between these 2 biases; they cannot be simultane-
ously eliminated [6].
The time-varying nature of infection also discombobulates a
matched cohort study [19]. Exposure to an HAI can occur at
any point during a hospital stay, but matched cohort studies tend
to compare infected and uninfected patients by their total hos-
pital stay. Infected patients can start generating costs due to an
HAI only after the infection has begun. If the timing of events
is ignored, costs that manifest before the HAI are included. Com-
bining preinfection outcomes with postinfection outcomes can
dramatically amplify confounding [19]. This bias is often called
time-dependent bias, and it has been shown mathematically to
always overstate the prolonging effect of an HAI on length of
stay [21]. Another closely related problem is a feedback effect
between an HAI and length of stay. Methods that fail to account
for this issue will produce biased estimates of extra length of stay
(q). Despite these severe limitations, matched cohort studies re-
main the most commonly used method for estimating cost and
produce heterogeneous results [6].
Methods that are less labor intensive than physician assess-
ment and that are methodologically superior to matched cohort
studies can be used; however, they are technically complex.
Most promising are statistical models that control for differ-
ences between patients at the analysis stage rather than at the
design stage. A statistical model can be built to describe the
relationship between a cost outcome, such as length of stay in
the hospital, and predictors of that outcome [43]. An advantage
is that multiple predictors can be included without selecting
out cases of HAI [24]. Statistical models, such as event history
analysis or survival analysis, can be used to account for the
time-varying nature of infection. They model the hazards or
rates between hospital admission, potential onset of HAI, dis-
charge alive from the hospital, and death in the hospital. Ad-
ditional time-dependent information, such as daily intubation
status, may also be included. Methods for both discrete and
continuous time are available [18, 44] and have their merits,
which we will not discuss here. These methods have been ap-
plied and show extra lengths of stay that are substantially lower
than those from methods that do not account for the timing
of events and important covariates [18, 45–47].
CONCLUSION
The “HAI costs a lot” approach to influencing decision making
has served the infection control community well. Important
articles have stated that very large costs arise from HAIs [38,
48–50]; all have been cited frequently and used to attract re-
sources toward infection control programs. The time has ar-
rived, however, for the methodological advances that have been
achieved in this area to be implemented by researchers. Com-
plete economic evaluations that include changes to all costs and
health benefits should be performed. The information used to
update these studies should be of high quality and bias free.
Those working in other areas of disease are using state-of-the-
art research methods to successfully make economic arguments
for increased spending. Examples include cost-effectiveness anal-
yses of different screening methods for colon cancer [51], of
interventions that improve physical activity [52], and of screening
for osteoporosis and treatment with hormone-replacement ther-
apy [53].
Inexorable growth in health care costs is forcing decision mak-
ers to respond to scarcity and work toward extracting greater
value from health care resources. The United States, Switzerland,
France, Germany, Belgium, Portugal, Austria, and Canada all
devote 110% of their gross domestic product to health spending
[54]. The time when reliable economic arguments will be par-
amount for obtaining extra resources—and even retaining ex-
isting ones—is close. Those working toward reducing the number
of HAIs should craft valid economic arguments on the basis of
sound methods and use them to build strong and cost-effective
infection control programs.
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